David Friedmann1, Sigune Goldacker2, Hans-Hartmut Peter2, Klaus Warnatz3. 1. Division of Immunodeficiency, Department of Rheumatology and Clinical Immunology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany; Center for Chronic Immunodeficiency (CCI), Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany; Faculty of Biology, University of Freiburg, Schaenzlestrasse 1, Freiburg, Germany. 2. Division of Immunodeficiency, Department of Rheumatology and Clinical Immunology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany; Center for Chronic Immunodeficiency (CCI), Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany. 3. Division of Immunodeficiency, Department of Rheumatology and Clinical Immunology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany; Center for Chronic Immunodeficiency (CCI), Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany. Electronic address: klaus.warnatz@uniklinik-freiburg.de.
Abstract
BACKGROUND: Vaccination against influenza is recommended for patients with common variable immunodeficiency (CVID), although humoral immune responses in these patients are impaired and the evidence of effective T-cell responses in CVID is not well established. OBJECTIVE: To determine plasmablast and T-cellular vaccination responses against influenza in patients with CVID. METHODS: Patients with CVID and healthy controls were vaccinated with the quadrivalent vaccine Influsplit Tetra 2018/2019. Before and 1 week after vaccination plasmablasts and circulating inducible costimulator-expressing T follicular helper cells were measured to determine positive vaccine responses in these patients. In addition, antigen-specific T cells were determined by their upregulation of CD25 and OX40 after in vitro restimulation with the vaccine. RESULTS: Most healthy controls but only 1 patient with CVID mounted a positive humoral immune response, measured by an increase in plasmablasts 1 week after vaccination. In contrast, most patients with CVID showed an increase in inducible costimulator+ T follicular helper cells and/or an increase in antigen-specific CD25+OX40+ T cells 1 week after vaccination, demonstrating a positive T-cellular immune response. CONCLUSIONS: Despite the remaining challenge of accurately assessing the complexity of T-cell responses, the recommendation of vaccinating patients with CVID against influenza is reasonable.
BACKGROUND: Vaccination against influenza is recommended for patients with common variable immunodeficiency (CVID), although humoral immune responses in these patients are impaired and the evidence of effective T-cell responses in CVID is not well established. OBJECTIVE: To determine plasmablast and T-cellular vaccination responses against influenza in patients with CVID. METHODS:Patients with CVID and healthy controls were vaccinated with the quadrivalent vaccine Influsplit Tetra 2018/2019. Before and 1 week after vaccination plasmablasts and circulating inducible costimulator-expressing T follicular helper cells were measured to determine positive vaccine responses in these patients. In addition, antigen-specific T cells were determined by their upregulation of CD25 and OX40 after in vitro restimulation with the vaccine. RESULTS: Most healthy controls but only 1 patient with CVID mounted a positive humoral immune response, measured by an increase in plasmablasts 1 week after vaccination. In contrast, most patients with CVID showed an increase in inducible costimulator+ T follicular helper cells and/or an increase in antigen-specific CD25+OX40+ T cells 1 week after vaccination, demonstrating a positive T-cellular immune response. CONCLUSIONS: Despite the remaining challenge of accurately assessing the complexity of T-cell responses, the recommendation of vaccinating patients with CVID against influenza is reasonable.
Authors: Cinzia Milito; Francesco Cinetto; Andrea Palladino; Giulia Garzi; Alessandra Punziano; Gianluca Lagnese; Riccardo Scarpa; Marcello Rattazzi; Anna Maria Pesce; Federica Pulvirenti; Giulia Di Napoli; Giuseppe Spadaro; Rita Carsetti; Isabella Quinti Journal: Biomedicines Date: 2022-04-29
Authors: Hannah Kinoshita; Jessica Durkee-Shock; Mariah Jensen-Wachspress; Vaishnavi V Kankate; Haili Lang; Christopher A Lazarski; Anjeni Keswani; Kathleen C Webber; Kimberly Montgomery-Recht; Magdalena Walkiewicz; Luigi D Notarangelo; Peter D Burbelo; Ivan Fuss; Jeffrey I Cohen; Catherine M Bollard; Michael D Keller Journal: J Clin Immunol Date: 2021-05-13 Impact factor: 8.542
Authors: Kai M T Sauerwein; Christoph B Geier; Roman F Stemberger; Hüseyin Akyaman; Peter Illes; Michael B Fischer; Martha M Eibl; Jolan E Walter; Hermann M Wolf Journal: Front Immunol Date: 2022-02-14 Impact factor: 7.561
Authors: Sneha Suresh; Joseline Zafack; Anne Pham-Huy; Beata Derfalvi; Manish Sadarangani; Athena McConnell; Bruce Tapiéro; Scott A Halperin; Gaston De Serres; Jeffrey M Pernica; Karina A Top Journal: Allergy Asthma Clin Immunol Date: 2022-04-09 Impact factor: 3.406